Bass AIA Challenge To Celgene Cancer Drug Patent Rejected

Law360, New York (November 18, 2015, 7:48 PM EST) -- The Patent Trial and Appeal Board has rejected a request by hedge fund manager Kyle Bass to review a Celgene Corp. patent on the compound for the cancer drug Revlimid, finding that his organization failed to show that it is likely invalid, weeks after agreeing to review other patents related to the drug.

In a decision Monday, the PTAB denied the petition seeking inter partes review under the America Invents Act of a patent on methods of reducing levels of tumor necrosis factor using certain compounds...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.